India Blood Gas & Cardiac Biomarker POC Analyzer Market Size, Share & Forecast, By Product Type, End User & Technology, 2026-2031

The market was valued at USD 71 million in 2025. The estimate includes analyzer sales, reagent and cartridge revenue, quality controls, connectivity and market-attributable service income for blood-gas and cardiac-biomarker point-of-care systems sold into India. Reagents and consumables represented approximately 78% of revenue, making installed-base utilization the principal economic driver. Hospitals remained the largest end-user group, while emergency departments and intensive-care units generated the highest recurring test volumes across the country.

The market is forecast to reach USD 121 million by 2031, representing a 9.29% CAGR from 2025. Annual test-equivalent volume is expected to expand from 15.2 million to 26.8 million as critical-care infrastructure, portable systems and cardiac-marker adoption broaden. Value growth remains slightly below volume growth because tender competition and localization reduce blended price, while higher-value troponin, NT-proBNP, D-dimer and multiplex assays partly offset that pressure and sustain supplier revenue momentum.

The profit pool will shift further toward cartridges, sensors, calibrators, middleware and managed-service contracts. Portable and cartridge-based systems are projected to represent 54% of placements by 2031, increasing the importance of proprietary consumables and remote fleet management across multi-site hospital networks. Reagent-rental agreements reduce hospital capital barriers while securing multi-year test volumes for suppliers. Localized consumable production can also improve gross margin by lowering foreign-exchange exposure, freight cost and inventory risk.

The most material risk is the interaction of import dependence, proprietary consumable pricing and fragmented service coverage. India still sources 70-80% of broader medical-device requirements through imports, while POC systems depend on validated cartridges and timely maintenance and calibration. Smaller hospitals may struggle to support premium per-test economics, and public tenders can compress margins or extend receivable cycles. Regulatory documentation and quality-control requirements further raise the cost of market entry and portfolio maintenance.

India ranks second among the selected Asian peer set, behind China and ahead of Indonesia, Thailand, Malaysia and the Philippines. Its 2025 market size is estimated at USD 71 million and its 9.3% forecast CAGR exceeds China and Thailand, although Indonesia grows slightly faster from a smaller base. India's advantage is a large disease burden and expanding critical-care pipeline; its disadvantage is lower hospital-bed density and uneven access outside leading cities.

Critical-care infrastructure expansion has the strongest near-term commercial impact because it directly creates analyzable sites, procurement budgets and recurring test volumes. Administrative approvals under PM-ABHIM covered 621 critical-care blocks and 744 integrated public-health laboratories by March 2026. Combined with a high cardiovascular burden and the clinical need for minute-level blood-gas and troponin results, these investments expand demand across public hospitals, medical colleges, district facilities and emergency-care networks across underserved states.